← All indications
Lymphomatoid Granulomatosis
An angiocentric and angiodestructive lymphoproliferative disorder primarily involving the lungs. It is caused by an Epstein-Barr virus-induced transformation of the B-cells, in a T-cell rich environment. Clinically and pathologically it resembles EXTRANODAL NK-T-CELL LYMPHOMA.
Drugs by status
Phase 2 trials (41)
- methylprednisolone
- ibritumomab tiuxetan
- urea
- bendamustine
- brentuximab vedotin
- busulfan
- lenalidomide
- prednisone
- doxorubicin
- gemcitabine
- oblimersen sodium
- tacrolimus
- naltrexone
- beclomethasone
- nivolumab
- msk-2206
- vincristine
- ifosfamide
- ipilimumab
- carboplatin
- allogeneic hematopoietic stem cells
- cyclosporine
- mycophenolate
- cyclophosphamide
- allogeneic lymphocytes
- alemtuzumab
- Anti-thymocyte Globulin (Rabbit)
- veliparib
- vorinostat
- autologous umbilical cord blood
- +11 more
Phase 1 trials (30)
- di-leu16-il2
- fau
- dexrazoxane
- autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
- sorafenib
- belinostat
- irinotecan
- devimistat
- entinostat
- paclitaxel
- ar-42
- in111 anti-cd45 monoclonal antibody bc8
- ispinesib
- methoxyamine
- alisertib
- morab-004
- ibrutinib
- sunitinib
- ro4929097
- bevacizumab
- tanespimycin
- dasatinib
- bortezomib
- acetic acid
- capecitabine
- y90 anti-cd45 monoclonal antibody bc8
- cediranib
- oxaliplatin
- obatoclax
- isotretinoin
Organizations
Organization Involved with Phase 2 Indications (19)
- Seattle Genetics
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Case Western Reserve University
- Cornell University
- University of Washington
- Northwestern University
- Ohio State University
- Rutgers University
- Stanford University
- Thomas Jefferson University
- University of Medicine and Dentistry of New Jersey
- University of Michigan
- University of Nebraska
- Mayo Clinic
- University of Chicago
- University of Texas at Houston
- State University of New York, Buffalo
- American Cancer Society, Inc.
Organization Involved with Phase 1 Indications (15)
- Morphotek
- Arno Therapeutics
- University of Pittsburgh
- AIDS Malignancy Consortium
- Cancer and Leukemia Group B (CALGB)
- Johns Hopkins University
- Southwest Oncology Group
- University of Rochester
- Wake Forest University
- Wayne State University
- University of Colorado, Denver
- City of Hope National Medical Center
- University of Wisconsin
- Damon Runyon Cancer Research Foundation
- St. Jude Children's Hospital